Search Hotels in Sausalito

If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Topics Intellectual Property

Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

December 24, 2025

Bristol Myers Squibb Co (NYSE:BMY) Presents a Classic Value Investing Case Amid Transition ↗

Topics Intellectual Property

December 24, 2025

Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges.

Via Chartmill

Topics Intellectual Property

Dividend Stocks Are the Gift that Will Keep On Giving You More Income in 2026 ↗

December 24, 2025

These dividend investments can provide you with a growing income stream in 2026.

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

Topics Economy

December 23, 2025

Via Stocktwits

Topics Government

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Via MarketMinute

Topics Intellectual Property

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Via MarketMinute

Topics Economy

Should Retirees Pull Their Money Out of the Stock Market in 2026? ↗

December 21, 2025

Even if you think the market will slump, selling your holdings isn't an ideal strategy.

Bristol-Myers Squibb Co (NYSE:BMY) Offers a High-Quality Dividend Profile for Income Investors ↗

Topics ETFs Economy Retirement

December 20, 2025

Bristol-Myers Squibb (BMY) offers a high 4.92% dividend yield with a strong growth history, backed by solid earnings and a satisfactory financial condition for income investors.

Via Chartmill

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

December 19, 2025

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

Topics Artificial Intelligence ETFs Economy

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

December 18, 2025

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

These 2 Healthcare Stocks Just Declared Dividend Raises ↗

December 17, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

Topics Intellectual Property

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

December 15, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its...

Via StockStory

Stay informed with the top movers within the S&P500 index on Monday. ↗

December 15, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions

December 15, 2025

Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative...

Via PredictStreet

Topics Intellectual Property Lawsuit Supply Chain

Top S&P500 movers in Monday's pre-market session ↗

December 15, 2025

The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Via Chartmill

2 Dividend Stocks to Double Up on Right Now ↗

December 14, 2025

These dividend growth machines could have considerable upside for long-term investors.

Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses.

Topics Economy Intellectual Property

The Smartest Dividend Stocks to Buy With $1,000 Right Now ↗

December 13, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Topics Economy Intellectual Property

Which S&P500 stocks are moving on Friday? ↗

December 12, 2025

Via Chartmill

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

December 12, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a...

Via StockStory

Topics Artificial Intelligence Supply Chain

Top S&P500 movers in Friday's session ↗

December 12, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Via Chartmill

The Best Turnaround Stock to Invest $1,000 in Right Now ↗

December 12, 2025

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

December 11, 2025

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more...

Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles

December 12, 2025

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

December 10, 2025

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

Bristol Myers Squibb Announces Dividend Increase

December 10, 2025

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

2 Pharmaceutical Stocks to Buy at a Discount ↗

December 10, 2025